; (II) structured to improve patient outcomes; and (III) reasonable in the context of industry data regarding baseline patient behavior, such as improved patient outcomes and measure performance. (B) Application of standardized pharmacy performance measures For plan years beginning on or after January 1, 2025, a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan that makes incentive payments to a pharmacy, or receives price concessions or any other remuneration paid by a pharmacy, based on measures of the performance or quality of work of the pharmacy, shall, for the purposes of such incentive payments and price concessions or fees with respect to covered part D drugs dispensed by such pharmacy, only use measures— (i) on the most recently updated list maintained by the Secretary under subparagraph (C), as listed under clause (ii) of such subparagraph